Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CalciMedica, Inc. Common Stock (CALC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CALC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -73.1% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 26.29M USD | Price to earnings Ratio - | 1Y Target Price 16 |
Price to earnings Ratio - | 1Y Target Price 16 | ||
Volume (30-day avg) 56912 | Beta 0.9 | 52 Weeks Range 1.81 - 6.26 | Updated Date 04/2/2025 |
52 Weeks Range 1.81 - 6.26 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.22 |
Earnings Date
Report Date 2025-03-26 | When Before Market | Estimate -0.3525 | Actual -1.22 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -87.15% | Return on Equity (TTM) -128.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7620738 | Price to Sales(TTM) - |
Enterprise Value 7620738 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.26 | Shares Outstanding 13481900 | Shares Floating 6693367 |
Shares Outstanding 13481900 | Shares Floating 6693367 | ||
Percent Insiders 17.6 | Percent Institutions 52.45 |
Analyst Ratings
Rating 4.67 | Target Price 17 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
CalciMedica, Inc. Common Stock
Company Overview
History and Background
CalciMedica is a clinical-stage biopharmaceutical company founded in 2006. It focuses on developing novel therapies for severe inflammatory and autoimmune diseases by targeting calcium release-activated calcium (CRAC) channels. Their lead compound is Auxora, aimed at treating acute pancreatitis and acute lung injury.
Core Business Areas
- Drug Development: Focuses on developing and commercializing Auxora, a CRAC channel inhibitor, for various inflammatory diseases.
Leadership and Structure
The leadership team includes Rachel Leheny, M.D., Ph.D., as CEO. The organizational structure comprises departments focused on research, clinical development, regulatory affairs, and commercial strategy.
Top Products and Market Share
Key Offerings
- Auxora: Auxora is CalciMedica's lead drug candidate. It is being developed for acute pancreatitis (AP) and acute respiratory distress syndrome (ARDS). Market share is currently 0% as it's not yet approved, representing future potential. Competitors include standard of care treatments and companies developing alternative AP and ARDS therapies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for inflammatory disease therapies is substantial and growing due to the rising prevalence of these conditions.
Positioning
CalciMedica is positioned as an innovator in CRAC channel inhibition for inflammatory diseases. Their competitive advantage lies in their proprietary Auxora molecule and its potential to address unmet needs in AP and ARDS.
Total Addressable Market (TAM)
The combined TAM for AP and ARDS is estimated to be in the billions of dollars. CalciMedica's positioning depends on Auxora's successful clinical development and regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel CRAC channel inhibitor mechanism
- Potential to address unmet needs in severe inflammatory diseases
- Strong intellectual property portfolio
Weaknesses
- Reliance on a single drug candidate (Auxora)
- Limited financial resources relative to larger pharmaceutical companies
- Clinical trial and regulatory risks
Opportunities
- Potential for strategic partnerships or acquisitions
- Expansion of Auxora's indications to other inflammatory diseases
- Positive clinical trial results leading to accelerated regulatory approval
Threats
- Competition from established pharmaceutical companies
- Failure of clinical trials
- Regulatory hurdles and delays
Competitors and Market Share
Key Competitors
- None (Auxora is a novel therapy)
- Various standard of care treatments for AP and ARDS
- Other companies developing therapies for inflammatory diseases (unspecified)
Competitive Landscape
CalciMedica's competitive advantage lies in its novel CRAC channel inhibition mechanism. However, it faces competition from established treatments and larger pharmaceutical companies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by clinical trial progress and expansion of development programs.
Future Projections: Future growth depends on successful clinical trials of Auxora and potential partnerships. Analyst estimates are based on forecasts for regulatory approval and commercialization.
Recent Initiatives: Recent initiatives include ongoing Phase 2b and Phase 3 clinical trials for Auxora in AP and ARDS, and exploration of additional indications for CRAC channel inhibition.
Summary
CalciMedica is a clinical-stage company with potential in the inflammatory disease space due to its novel mechanism with Auxora. The company is reliant on Auxora's success in clinical trials, which poses a significant risk. Its limited financial resources require careful management and potential strategic partnerships. Positive clinical results are critical for the company's future growth and shareholder value.
Similar Companies
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information is based on publicly available data and analyst estimates, which are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CalciMedica, Inc. Common Stock
Exchange NASDAQ | Headquaters La Jolla, CA, United States | ||
IPO Launch date 2020-09-25 | CEO & Director Dr. A. Rachel Leheny Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.calcimedica.com |
Full time employees 13 | Website https://www.calcimedica.com | ||
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.